» Articles » PMID: 3975631

Reversal of Oncogenesis by the Expression of a Major Histocompatibility Complex Class I Gene

Overview
Journal Science
Specialty Science
Date 1985 Apr 5
PMID 3975631
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

The classical transplantation antigens (the major histocompatibility complex class I antigens) play a key role in host defense against cells expressing foreign antigens. Several naturally occurring tumors and virally transformed cells show an overall suppression of these surface antigens. Since the class I molecules are required in the presentation of neoantigens on tumor cells to the cytotoxic T lymphocytes, their absence from the cell surface may lead to the escape of these tumors from immunosurveillance. To test this possibility, a functional class I gene was transfected into human adenovirus 12-transformed mouse cells that do not express detectable levels of class I antigens; the transformants were tested for expression of the transfected gene and for changes in oncogenicity. The expression of a single class I gene, introduced by DNA-mediated gene transfer into highly tumorigenic adenovirus 12-transformed cells, was sufficient to abrogate the oncogenicity of these cells. This finding has important implications for the regulation of the malignant phenotype in certain tumors and for the potential modulation of oncogenicity through derepression of the endogenous class I genes.

Citing Articles

Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors.

Alotaibi F, Alshammari K, Alotaibi B, Alsaab H Front Pharmacol. 2024; 14:1280591.

PMID: 38264532 PMC: 10803447. DOI: 10.3389/fphar.2023.1280591.


Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours.

Dada S, Ellis S, Wood C, Nohara L, Dreier C, Garcia N Front Immunol. 2023; 13:982082.

PMID: 36923728 PMC: 10010394. DOI: 10.3389/fimmu.2022.982082.


CAR-T cell therapy in ovarian cancer: from the bench to the bedside.

Zhu X, Cai H, Zhao L, Ning L, Lang J Oncotarget. 2017; 8(38):64607-64621.

PMID: 28969098 PMC: 5610030. DOI: 10.18632/oncotarget.19929.


Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.

Del Campo A, Carretero J, Munoz J, Zinchenko S, Ruiz-Cabello F, Gonzalez-Aseguinolaza G Cancer Gene Ther. 2014; 21(8):317-32.

PMID: 24971583 DOI: 10.1038/cgt.2014.32.


Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?.

Brahmer J Semin Oncol. 2014; 41(1):126-32.

PMID: 24565586 PMC: 4732704. DOI: 10.1053/j.seminoncol.2013.12.014.